- Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy
In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association (CMTA) and the Muscular Dystrophy Association (MDA), researchers led by Alexia Kagiava, PhD, at the Cyprus Institute of Neurology and Genetics are pioneering the use ...
Read more ... - Repurposing Drugs for CMT1A: An Encouraging Approach
Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form of CMT, caused by having an extra copy of the PMP22 gene. This results in PMP22 overexpression, leading to excessive PMP22 protein in Schwann cells, ...
Read more ... - DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR) and led by CMTA-STAR Advisory Board member Mario Saporta, MD, PhD, have made significant progress in ...
Read more ... - CMT-SORD: Share Your Story
CMT-SORD: What is Your Story?
For many with CMT, the journey through diagnosis, acceptance, and living with this progressive disease can be isolating. Most research is conducted through a clinical lens that aims to improve symptoms. ...
Read more ... - Chris Oviatt – Golfer with CMT
Chris Oviatt is a golfer from Oregon who was diagnosed with Charcot-Marie-Tooth disease (CMT) in 1987. As she prepares for the US Adaptive Open in Kansas, Chris took time to chat with CMTA’s CEO Dr. ...
Read more ...